Tuesday, 25 September 2018

IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer

submitted by /u/BSP_
[link] [comments]

from Health https://ift.tt/2xC5cl9
via IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)